New Study Pinpoints Genetic Source of Rare Form of Muscular Dystrophy

November 12, 2012

Rabi Tawil, M.D.

A new study appearing today in the journal Nature Genetics by an international team of researchers has solved the complex genetic mystery behind a form of muscular dystrophy. The scientists have discovered that a rare variant of facioscapulohumeral muscular dystrophy (FSHD), called type 2, is the result of two unrelated genetic flaws that come together to ultimately produce toxins that damage muscle cells and trigger the symptoms of the disease.

 “The discovery of the complex and elusive source of FSHD type 2 is the result of not only a unique international partnership of scientists, but also the extraordinary cooperation of the families who are burdened by this disease,” said University of Rochester Medical Center (URMC) neurologist Rabi Tawil, M.D., a senior co-author of the study. “Here in Rochester, we have evaluated many patients – often for several years – who clearly suffered from FSHD, but did not meet the common genetic profile of the disease. This discovery will help us better diagnose these patients and help guide research that could lead to new treatments.”

The study was conducted by a team of researchers from URMC’s Fields Center for FSHD & Neuromuscular Research, the Leiden University Medical Center in the Netherlands, the University of Washington, and the Fred Hutchinson Cancer Research Center in Seattle.

FSHD is the third most common form of muscular dystrophy. The first symptoms of the disease usually appear in the form of muscle weakness in the upper body – including the arms, shoulders, and face. Eventually, these symptoms spread to the rest of the body. While not fatal, the disease can lead to significant disability and many patients end up in a wheelchair.   An estimated 500,000 people worldwide suffer from this disease.

The genetic cause of FSHD type 1 – the more common form of the disease – was first revealed by the same group of researchers in a study that appeared in journal Science in 2010.  In that paper, the scientists zeroed in on a specific segment of genetic code called a macrosatellite repeat that appears at the end of chromosome 4, essentially a genetic “stutter” that results in a section of code being replicated multiple times. 

The human genetic code was thought to be full of “junk” or inactive genes often contained in macrosatellite repeat sequences such as the one seen in FSHD. However, these regions of repeated genetic code are now understood to be actively switched on and off and help regulate the function of many other genes.  When the normal regulation of gene expression is disrupted, such as occurs in FSHD, the effect is devastating. 

People without the disease actually have a large number of repeats. Consequently, this section of the code is longer and folds tightly back upon itself like a ball of twine. This prevents an active piece of code – called DUX4 – which is bound up within the macrosatellite repeat from being accessed. DUX4 carries instructions to create a protein that – while found in other parts of the body – is toxic to muscle cells. 

By contrast, people with the disease possess a small number repeats (less than 10). The Science study found that in these instances the DNA is more loosely bound and exposed allowing the genetic instructions in DUX4 to be used by the muscle cells to build proteins. People with FSHD also possess a snippet of genetic code adjacent to the repeats – called an A allele –that serves to stabilize the message from the DUX4 code. In people with these unfortunate set of conditions (short number of repeats followed by an A allele), the result is the production of a protein that breaks down muscle cells causing the symptoms of the disease.

“Most genetic mutations reduce the production of a protein, or a mutated gene might produce a detrimental protein,” said Daniel Miller, M.D., Ph.D., and associate professor of pediatrics at the University of Washington. “FSHD is unusual because it is most often caused by genetic deletions that paradoxically result in the production of DUX4 in the wrong tissue at the wrong time. “

While this phenomenon explained the trigger for the vast majority of FSHD patients, there remained a small number of individuals – 5 percent of patients with the disease – that did not meet this genetic profile. These patients, dubbed by researchers as exhibiting FSHD type 2, possessed the longer D4Z4 repeats found in healthy individuals, however, their symptoms where identical to other FSHD patients.   

To understand the cause of this FSHD variant, researchers analyzed the genetic profiles of 12 families with the disease. The genetic mutations that cause FSHD are inherited. By examining the code of patients with FSHD type 2 and that of their unaffected parents and siblings, the researchers could then identify the common genetic factors and begin to understand how they may impact each other.

“The breakthrough came when we realized that in some of these FSHD type 2 families this open macrosatellite structure segregates in the family independent of the length of the repeat,” said Silvere van der Maarel, Ph.D., professor of human genetics at the Leiden University Medical Center. “This observation allowed the identification of the genetic flaw that causes this opening of the repeat structure.”

This investigation ultimately led the team to yet another culprit on a different chromosome. In healthy cells, one of the factors that helps bind long strands of the chromosomes tightly together is a chemical process called methylation. In FSHD, the absence of these chemical links enables the macrosatellite repeat structure to unravel or open up – regardless of its length – exposing the DUX4 code.   The researchers found that this occurred in patients who also possessed a mutation in a gene called SMCHD1, which regulates the methylation process and consequently how tightly genetic structures are bound together.   In patients with FSHD type 2, just as in FSHD type 1, this flaw works in concert with the A allele code to create the conditions in which the toxic proteins that are the source of the disease are mistakenly produced. 

“Many diseases caused by a single gene mutation were identified over the last several decades, but it has been more difficult to identify the genetic basis of diseases caused by the combination of more than one genetic variant,” said Stephen Tapscott, M.D., Ph.D., a co-investigator at the Fred Hutchinson Cancer Research Center. “Recent advances in DNA sequencing made this study possible and it is likely that other diseases caused by the inheritance of multiple genetic variants will be identified in the coming years.”

This understanding of the source and mechanisms of the disease has helped researchers identify junctures during which the disease process could be intercepted or altered. The findings also indicate that similar treatments could be developed that impact patients with both types of FSHD.  

In addition to Tawil, Van der Maarel, and Miller, other authors of the Nature Genetics paper include:

·         University of Rochester Medical Center: Colleen Donlin-Smith;

·         Leiden University Medical Center: Richard Lemmers, Judit Balog, Patrick van der Vliet, Kirsten Straasheijm, Yvonne Krom, Rinse Klooster, Yu Sun, Johan den Dunnen, Jessica de Greef, Annemieke Aartsma-Rus, Rune Frants, , Quinta Helmer, Bert Bakker;

·         University of Washington: Lisa Petek, Gregory Block, Amanda Amell, and Michael Bamshad

·         Radboud University Nijmegen Medical Centre (Netherlands): George Padberg and Baziel van Engelen;

·         Academic Medical Center (Amsterdam, Netherlands): Marianne de Visser;

·         Nice University Hospital (France): Claude Desnuelle and Sabrina Sacconi; and

·         Fred Hutchinson Cancer Research Center (Seattle): Stephen Tapscott and Galina Filippova.

Funding to conduct the study came from the National Institutes of Neurological Disorders and Stroke, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Human Genome Institute, National Genetics Institute, the Muscular Dystrophy Association, and the URMC’s Fields Center for FSHD & Neuromuscular Research.

For Media Inquiries:
Mark Michaud
(585) 273-4790
Email Mark Michaud